TY - STD TI - Surveillance, E., and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: incidence—SEER 9 Regs Research Data, Nov 2017 Sub (1973–2015) − Linked To County Attributes - Total U.S., 1969–2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission. UR - http://www.seer.cancer.gov ID - ref1 ER - TY - JOUR AU - Dohner, H. AU - Weisdorf, D. J. AU - Bloomfield, C. D. PY - 2015 DA - 2015// TI - Acute myeloid leukemia JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMra1406184 DO - 10.1056/NEJMra1406184 ID - Dohner2015 ER - TY - JOUR AU - Deschler, B. PY - 2006 DA - 2006// TI - Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches JO - Haematologica VL - 91 ID - Deschler2006 ER - TY - JOUR AU - Burnett, A. AU - Wetzler, M. AU - Lowenberg, B. PY - 2011 DA - 2011// TI - Therapeutic advances in acute myeloid leukemia JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.30.1820 DO - 10.1200/JCO.2010.30.1820 ID - Burnett2011 ER - TY - JOUR AU - Lichtman, M. A. PY - 2013 DA - 2013// TI - A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3 JO - Blood Cells Mol Dis VL - 50 UR - https://doi.org/10.1016/j.bcmd.2012.10.005 DO - 10.1016/j.bcmd.2012.10.005 ID - Lichtman2013 ER - TY - JOUR AU - Lowenberg, B. PY - 2011 DA - 2011// TI - Cytarabine dose for acute myeloid leukemia JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1010222 DO - 10.1056/NEJMoa1010222 ID - Lowenberg2011 ER - TY - JOUR AU - Burnett, A. K. PY - 2015 DA - 2015// TI - A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients JO - Blood VL - 125 UR - https://doi.org/10.1182/blood-2015-01-623447 DO - 10.1182/blood-2015-01-623447 ID - Burnett2015 ER - TY - JOUR AU - Karp, J. E. PY - 1989 DA - 1989// TI - In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia JO - Blood VL - 73 ID - Karp1989 ER - TY - JOUR AU - Norsworthy, K. J. PY - 2017 DA - 2017// TI - Timed sequential therapy for acute myelogenous leukemia: results of a retrospective study of 301 patients and review of the literature JO - Leuk Res VL - 61 UR - https://doi.org/10.1016/j.leukres.2017.08.009 DO - 10.1016/j.leukres.2017.08.009 ID - Norsworthy2017 ER - TY - JOUR AU - Geller, R. B. PY - 1989 DA - 1989// TI - A two-step timed sequential treatment for acute myelocytic leukemia JO - Blood VL - 74 ID - Geller1989 ER - TY - JOUR AU - Herzig, R. H. PY - 1983 DA - 1983// TI - High-dose cytosine arabinoside therapy for refractory leukemia JO - Blood VL - 62 ID - Herzig1983 ER - TY - JOUR AU - Jen, E. Y. PY - 2018 DA - 2018// TI - FDA approval: Gemtuzumab Ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-3179 DO - 10.1158/1078-0432.CCR-17-3179 ID - Jen2018 ER - TY - JOUR AU - Kindler, T. AU - Lipka, D. B. AU - Fischer, T. PY - 2010 DA - 2010// TI - FLT3 as a therapeutic target in AML: still challenging after all these years JO - Blood VL - 116 UR - https://doi.org/10.1182/blood-2010-04-261867 DO - 10.1182/blood-2010-04-261867 ID - Kindler2010 ER - TY - JOUR AU - Kelly, L. M. PY - 2002 DA - 2002// TI - FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model JO - Blood VL - 99 UR - https://doi.org/10.1182/blood.V99.1.310 DO - 10.1182/blood.V99.1.310 ID - Kelly2002 ER - TY - JOUR AU - Kottaridis, P. D. PY - 2001 DA - 2001// TI - The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials JO - Blood VL - 98 UR - https://doi.org/10.1182/blood.V98.6.1752 DO - 10.1182/blood.V98.6.1752 ID - Kottaridis2001 ER - TY - JOUR AU - Whitman, S. P. PY - 2001 DA - 2001// TI - Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study JO - Cancer Res VL - 61 ID - Whitman2001 ER - TY - JOUR AU - Thiede, C. PY - 2002 DA - 2002// TI - Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis JO - Blood VL - 99 UR - https://doi.org/10.1182/blood.V99.12.4326 DO - 10.1182/blood.V99.12.4326 ID - Thiede2002 ER - TY - JOUR AU - Stone, R. M. PY - 2017 DA - 2017// TI - Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1614359 DO - 10.1056/NEJMoa1614359 ID - Stone2017 ER - TY - JOUR AU - Stone, R. M. PY - 2005 DA - 2005// TI - Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 JO - Blood VL - 105 UR - https://doi.org/10.1182/blood-2004-03-0891 DO - 10.1182/blood-2004-03-0891 ID - Stone2005 ER - TY - JOUR AU - Knapper, S. PY - 2006 DA - 2006// TI - A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy JO - Blood VL - 108 UR - https://doi.org/10.1182/blood-2006-04-015560 DO - 10.1182/blood-2006-04-015560 ID - Knapper2006 ER - TY - JOUR AU - Fischer, T. PY - 2010 DA - 2010// TI - Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3 JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2010.28.9678 DO - 10.1200/JCO.2010.28.9678 ID - Fischer2010 ER - TY - JOUR AU - DeAngelo, D. J. PY - 2006 DA - 2006// TI - Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics JO - Blood VL - 108 UR - https://doi.org/10.1182/blood-2006-02-005702 DO - 10.1182/blood-2006-02-005702 ID - DeAngelo2006 ER - TY - JOUR AU - Fiedler, W. PY - 2005 DA - 2005// TI - A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease JO - Blood VL - 105 UR - https://doi.org/10.1182/blood-2004-05-1846 DO - 10.1182/blood-2004-05-1846 ID - Fiedler2005 ER - TY - JOUR AU - Zhang, W. PY - 2008 DA - 2008// TI - Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia JO - J Natl Cancer Inst VL - 100 UR - https://doi.org/10.1093/jnci/djm328 DO - 10.1093/jnci/djm328 ID - Zhang2008 ER - TY - JOUR AU - Smith, B. D. PY - 2004 DA - 2004// TI - Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia JO - Blood VL - 103 UR - https://doi.org/10.1182/blood-2003-11-3775 DO - 10.1182/blood-2003-11-3775 ID - Smith2004 ER - TY - JOUR AU - Cortes, J. E. PY - 2013 DA - 2013// TI - Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2013.48.8783 DO - 10.1200/JCO.2013.48.8783 ID - Cortes2013 ER - TY - JOUR AU - Perl, A. E. PY - 2017 DA - 2017// TI - Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30416-3 DO - 10.1016/S1470-2045(17)30416-3 ID - Perl2017 ER - TY - STD TI - Rydapt Prescribing Information. 2017; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf ID - ref28 ER - TY - JOUR AU - Weisberg, E. PY - 2002 DA - 2002// TI - Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412 JO - Cancer Cell VL - 1 UR - https://doi.org/10.1016/S1535-6108(02)00069-7 DO - 10.1016/S1535-6108(02)00069-7 ID - Weisberg2002 ER - TY - JOUR AU - Ikegami, Y. AU - Yano, S. AU - Nakao, K. PY - 1996 DA - 1996// TI - Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells JO - Jpn J Pharmacol VL - 70 UR - https://doi.org/10.1254/jjp.70.65 DO - 10.1254/jjp.70.65 ID - Ikegami1996 ER - TY - JOUR AU - Levis, M. PY - 2006 DA - 2006// TI - Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors JO - Blood VL - 108 UR - https://doi.org/10.1182/blood-2006-04-015743 DO - 10.1182/blood-2006-04-015743 ID - Levis2006 ER - TY - JOUR AU - Stone, R. M. PY - 2012 DA - 2012// TI - Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia JO - Leukemia VL - 26 UR - https://doi.org/10.1038/leu.2012.115 DO - 10.1038/leu.2012.115 ID - Stone2012 ER - TY - JOUR AU - Levis, M. J. PY - 2018 DA - 2018// TI - Development of a novel next-generation sequencing (NGS)-based assay for measurable residual disease (MRD) in <em>FLT3</em>-ITD AML and its potential clinical application in patients treated with chemotherapy plus FLT3 inhibitors JO - Blood VL - 132 ID - Levis2018 ER - TY - STD TI - Vyxeos Prescribing Information. 2017; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf ID - ref34 ER - TY - JOUR AU - Lancet, J. E. PY - 2016 DA - 2016// TI - Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.34.15_suppl.7000 DO - 10.1200/JCO.2016.34.15_suppl.7000 ID - Lancet2016 ER - TY - STD TI - IDHIFA Prescribing Information. 2017; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf. [cited 2018 December 20] UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf ID - ref36 ER - TY - JOUR AU - Stein, E. M. PY - 2017 DA - 2017// TI - Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia JO - Blood VL - 130 UR - https://doi.org/10.1182/blood-2017-04-779405 DO - 10.1182/blood-2017-04-779405 ID - Stein2017 ER - TY - STD TI - Mylotarg Prescribing Information. 2018; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761060s001lbl.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761060s001lbl.pdf ID - ref38 ER - TY - JOUR AU - Bross, P. F. PY - 2001 DA - 2001// TI - Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia JO - Clin Cancer Res VL - 7 ID - Bross2001 ER - TY - JOUR AU - Norsworthy, K. J. PY - 2018 DA - 2018// TI - FDA approval summary: Mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia JO - Oncologist VL - 23 UR - https://doi.org/10.1634/theoncologist.2017-0604 DO - 10.1634/theoncologist.2017-0604 ID - Norsworthy2018 ER - TY - STD TI - Xospata Prescribing Information. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf ID - ref41 ER - TY - STD TI - Daurismo Prescribing Information. 2018; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf ID - ref42 ER - TY - STD TI - Lee B, Onofrei CD, Sheski F. The culprit midostaurin in a case of drug-induced pneumonitis, in D35. Drug induced lung disease: case reports: American Thoracic Society; 2018. p. A6647. https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A6647. UR - https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A6647 ID - ref43 ER - TY - STD TI - Venclexta Prescribing Information. 2018; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208573s009lbl.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208573s009lbl.pdf ID - ref44 ER - TY - STD TI - Rydapt Product Information. 2017 [cited 2019 June 28]; Available from: https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf. UR - https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf ID - ref45 ER - TY - STD TI - Midostaurin Medical Review(s). 2017 [cited 2019 June 28]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf ID - ref46 ER - TY - STD TI - Larson RA, et al. An analysis of maintenance therapy and post-midostaurin outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. 2017;130(Suppl 1):145. http://www.bloodjournal.org/content/130/Suppl_1/145?sso-checked=true. UR - http://www.bloodjournal.org/content/130/Suppl_1/145?sso-checked=true ID - ref47 ER - TY - STD TI - Maziarz RTT, et al. Radius: a phase 2 randomized trial investigating standard of care ± midostaurin after allogeneic stem cell transplant in FLT3−ITD-mutated AML. 2018;132(Suppl 1):662. http://www.bloodjournal.org/content/132/Suppl_1/662. UR - http://www.bloodjournal.org/content/132/Suppl_1/662 ID - ref48 ER - TY - JOUR AU - Perl, A. E. PY - 2016 DA - 2016// TI - Final results of the Chrysalis trial: a first-in-human phase 1/2 dose-escalation, dose-expansion study of Gilteritinib (ASP2215) in patients with relapsed/refractory acute myeloid leukemia (R/R AML) JO - Blood VL - 128 ID - Perl2016 ER - TY - BOOK AU - Perl, A. AU - Giovanni, M. AU - Jorge, C. AU - Andreas, N. AU - Berman, E. AU - Stefania, P. AU - Pau, M. AU - Baer Maria, R. AU - Larson Richard, A. AU - Celalettin, U. AU - Francesco, F. AU - Antonio, D. S. AU - Robert, S. AU - Rebecca, O. AU - Margaret, K. AU - Fabio, C. AU - Wen-Chien, C. AU - Nikolai, P. AU - Christian, R. AU - Hisayuki, Y. AU - Naoko, H. AU - Sung-Soo, Y. AU - Je-Hwan, L. AU - Timothy, P. AU - Fathi Amir, T. AU - Chaofeng, L. AU - Xuan, L. AU - Erkut, B. AU - Levis Mark, J. PY - 2019 DA - 2019// TI - Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial PB - AACR: Proceedings of the 110th Annual Meeting of the American Association for Cancer Research CY - Atlanta, GA ID - Perl2019 ER - TY - JOUR AU - Sexauer, A. PY - 2012 DA - 2012// TI - Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-01-402545 DO - 10.1182/blood-2012-01-402545 ID - Sexauer2012 ER - TY - JOUR AU - Fathi, A. T. PY - 2013 DA - 2013// TI - FLT3 inhibitor-induced neutrophilic dermatosis JO - Blood VL - 122 UR - https://doi.org/10.1182/blood-2013-01-478172 DO - 10.1182/blood-2013-01-478172 ID - Fathi2013 ER - TY - JOUR AU - Varadarajan, N. PY - 2016 DA - 2016// TI - FLT3 inhibitor-associated neutrophilic dermatoses JO - JAMA Dermatol VL - 152 UR - https://doi.org/10.1001/jamadermatol.2015.6121 DO - 10.1001/jamadermatol.2015.6121 ID - Varadarajan2016 ER - TY - JOUR AU - Patel, K. P. PY - 2011 DA - 2011// TI - Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features JO - Am J Clin Pathol VL - 135 UR - https://doi.org/10.1309/AJCPD7NR2RMNQDVF DO - 10.1309/AJCPD7NR2RMNQDVF ID - Patel2011 ER - TY - JOUR AU - Ward, P. S. PY - 2010 DA - 2010// TI - The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate JO - Cancer Cell VL - 17 UR - https://doi.org/10.1016/j.ccr.2010.01.020 DO - 10.1016/j.ccr.2010.01.020 ID - Ward2010 ER - TY - JOUR AU - Yang, H. PY - 2012 DA - 2012// TI - IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-1773 DO - 10.1158/1078-0432.CCR-12-1773 ID - Yang2012 ER - TY - JOUR AU - Stein, E. M. PY - 2019 DA - 2019// TI - Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib JO - Blood VL - 133 UR - https://doi.org/10.1182/blood-2018-08-869008 DO - 10.1182/blood-2018-08-869008 ID - Stein2019 ER - TY - STD TI - Enasidenib Multi-Discipline Review/Summary, Clinical, Non-Clinical. 2017 December 12, 2018]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209606Orig1s000MultidisciplineR.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209606Orig1s000MultidisciplineR.pdf ID - ref58 ER - TY - STD TI - Norsworthy KJ, M Flora, Ward Ashley F, Przepiorka Donna, Deisseroth Albert B, Farrell Ann T, Pazdur Richard, Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA). ASH Annual Meeting, 2018. Session 615: Oral Presentation. ID - ref59 ER - TY - BOOK PY - 2017 DA - 2017// TI - Enasidenib. Center for drug evaluation and research ID - ref60 ER - TY - STD TI - Tibsovo prescribing information. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf ID - ref61 ER - TY - STD TI - Norsworthy KJ, et al. FDA approval summary: Ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation. Clin Cancer Res. 2019; p. clincanres.3749.2018 ID - ref62 ER - TY - JOUR AU - DiNardo, C. D. PY - 2018 DA - 2018// TI - Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1716984 DO - 10.1056/NEJMoa1716984 ID - DiNardo2018 ER - TY - STD TI - TIBSOVO Prescribing Information. 2018 [cited 2018 December 20]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf ID - ref64 ER - TY - JOUR AU - Dinardo, C. D. PY - 2019 DA - 2019// TI - Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML) JO - J Clin Oncol VL - 37 ID - Dinardo2019 ER - TY - JOUR AU - Pan, R. PY - 2014 DA - 2014// TI - Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia JO - Cancer Discov VL - 4 UR - https://doi.org/10.1158/2159-8290.CD-13-0609 DO - 10.1158/2159-8290.CD-13-0609 ID - Pan2014 ER - TY - JOUR AU - Konopleva, M. PY - 2006 DA - 2006// TI - Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia JO - Cancer Cell VL - 10 UR - https://doi.org/10.1016/j.ccr.2006.10.006 DO - 10.1016/j.ccr.2006.10.006 ID - Konopleva2006 ER - TY - JOUR AU - Tsao, T. PY - 2012 DA - 2012// TI - Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells JO - Ann Hematol VL - 91 UR - https://doi.org/10.1007/s00277-012-1537-8 DO - 10.1007/s00277-012-1537-8 ID - Tsao2012 ER - TY - JOUR AU - Konopleva, M. PY - 2016 DA - 2016// TI - Efficacy and biological correlates of response in a phase II study of Venetoclax monotherapy in patients with acute myelogenous leukemia JO - Cancer Discov VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-16-0313 DO - 10.1158/2159-8290.CD-16-0313 ID - Konopleva2016 ER - TY - JOUR AU - DiNardo, C. D. PY - 2019 DA - 2019// TI - Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia JO - Blood VL - 133 UR - https://doi.org/10.1182/blood-2018-08-868752 DO - 10.1182/blood-2018-08-868752 ID - DiNardo2019 ER - TY - JOUR AU - Lancet, J. E. PY - 2018 DA - 2018// TI - CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional Cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.77.6112 DO - 10.1200/JCO.2017.77.6112 ID - Lancet2018 ER - TY - JOUR AU - Lancet, J. E. PY - 2017 DA - 2017// TI - Efficacy and safety of CPX-351 versus 7+3 in older adults with secondary acute myeloid leukemia: combined subgroup analysis of phase 2 and phase 3 studies JO - Blood VL - 130 ID - Lancet2017 ER - TY - JOUR AU - Tardi, P. PY - 2009 DA - 2009// TI - In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy JO - Leuk Res VL - 33 UR - https://doi.org/10.1016/j.leukres.2008.06.028 DO - 10.1016/j.leukres.2008.06.028 ID - Tardi2009 ER - TY - JOUR AU - Cortes, J. E. PY - 2018 DA - 2018// TI - Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results JO - Am J Hematol VL - 93 UR - https://doi.org/10.1002/ajh.25238 DO - 10.1002/ajh.25238 ID - Cortes2018 ER - TY - STD TI - Cortes JE, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2018; ID - ref75 ER - TY - JOUR AU - Aberger, F. PY - 2017 DA - 2017// TI - Acute myeloid leukemia - strategies and challenges for targeting oncogenic hedgehog/GLI signaling JO - Cell Commun Signal VL - 15 UR - https://doi.org/10.1186/s12964-017-0163-4 DO - 10.1186/s12964-017-0163-4 ID - Aberger2017 ER - TY - JOUR AU - Castaigne, S. PY - 2012 DA - 2012// TI - Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study JO - Lancet VL - 379 UR - https://doi.org/10.1016/S0140-6736(12)60485-1 DO - 10.1016/S0140-6736(12)60485-1 ID - Castaigne2012 ER - TY - JOUR AU - Wei, A. H. PY - 2019 DA - 2019// TI - Venetoclax combined with low-dose Cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.18.01600 DO - 10.1200/JCO.18.01600 ID - Wei2019 ER - TY - JOUR AU - Wei, A. PY - 2018 DA - 2018// TI - Venetoclax with low-dose Cytarabine induces rapid, deep, and durable responses in previously untreated older adults with AML ineligible for intensive chemotherapy JO - Blood VL - 132 ID - Wei2018 ER - TY - STD TI - Xospata Multi-Discipline Review/Summary, Clinical, Non-Clinical. 2018; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211349Orig1s000MultidisciplineR.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211349Orig1s000MultidisciplineR.pdf ID - ref80 ER - TY - STD TI - Perl AE, et al. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial. in AACR Annual Meeting, vol. 2019. AACR: Atlanta; 2019. https://www.abstractsonline.com/pp8/#!/6812/presentation/9835. UR - https://www.abstractsonline.com/pp8/#!/6812/presentation/9835 ID - ref81 ER - TY - JOUR AU - Taksin, A. L. PY - 2007 DA - 2007// TI - High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group JO - Leukemia VL - 21 UR - https://doi.org/10.1038/sj.leu.2404434 DO - 10.1038/sj.leu.2404434 ID - Taksin2007 ER - TY - JOUR AU - Amadori, S. PY - 2016 DA - 2016// TI - Gemtuzumab Ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.64.0060 DO - 10.1200/JCO.2015.64.0060 ID - Amadori2016 ER - TY - JOUR AU - Castaigne, S. PY - 2014 DA - 2014// TI - Final analysis of the ALFA 0701 study JO - Blood VL - 124 ID - Castaigne2014 ER - TY - STD TI - Norsworthy, K.J., et al., FDA approval summary: Glasdegib for newly diagnosed acute myeloid leukemia. Clin Cancer Res. 2019. https://doi.org/10.1158/1078-0432.CCR-19-0365. [Epub ahead of print]. ID - ref85 ER - TY - STD TI - Ivosidenib Multi-Discipline Review/Summary, Clinical, Non-Clinical. 2018; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211192Orig1s000MultidisciplineR.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211192Orig1s000MultidisciplineR.pdf ID - ref86 ER - TY - JOUR AU - Wei, A. PY - 2017 DA - 2017// TI - Phase 1/2 study of Venetoclax with low-dose Cytarabine in treatment-naive, elderly patients with acute myeloid leukemia unfit for intensive chemotherapy: 1-year outcomes JO - Blood VL - 130 ID - Wei2017 ER - TY - BOOK AU - Wei, A. S. AU - Stephen, A. AU - Jing-Zhou, H. AU - Fiedler, W. AU - Lin, T. L. AU - Walter, R. B. AU - Enjeti, A. K. AU - Hong, W. -. J. AU - Chyla, B. AU - Popovic, R. AU - Fakouhi, K. AU - Xu, T. AU - Hayslip, J. AU - Roboz, G. J. PY - 2018 DA - 2018// TI - Venetoclax with low-dose Cytarabine induces rapid, deep, and durable responses in previously untreated older adults with AML ineligible for intensive chemotherapy ASH annual meeting: session 615 ID - Wei2018 ER - TY - STD TI - Glasdegib Medical Review(s). 2018; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210656Orig1s000MedR.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210656Orig1s000MedR.pdf ID - ref89 ER - TY - JOUR AU - Krauss, A. C. PY - 2019 DA - 2019// TI - FDA approval summary: (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia JO - Clin Cancer Res VL - 25 UR - https://doi.org/10.1158/1078-0432.CCR-18-2990 DO - 10.1158/1078-0432.CCR-18-2990 ID - Krauss2019 ER - TY - JOUR AU - Vardiman, J. W. PY - 2009 DA - 2009// TI - The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes JO - Blood VL - 114 UR - https://doi.org/10.1182/blood-2009-03-209262 DO - 10.1182/blood-2009-03-209262 ID - Vardiman2009 ER - TY - JOUR AU - Arber, D. A. PY - 2016 DA - 2016// TI - The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2016-03-643544 DO - 10.1182/blood-2016-03-643544 ID - Arber2016 ER - TY - JOUR AU - Granfeldt Østgård, L. S. PY - 2015 DA - 2015// TI - Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a National Population-Based Cohort Study JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.60.0890 DO - 10.1200/JCO.2014.60.0890 ID - Granfeldt Østgård2015 ER - TY - JOUR AU - Feldman, E. J. PY - 2011 DA - 2011// TI - First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.30.5961 DO - 10.1200/JCO.2010.30.5961 ID - Feldman2011 ER - TY - JOUR AU - Lancet, J. E. PY - 2014 DA - 2014// TI - Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML JO - Blood VL - 123 UR - https://doi.org/10.1182/blood-2013-12-540971 DO - 10.1182/blood-2013-12-540971 ID - Lancet2014 ER - TY - JOUR AU - Sievers, E. L. PY - 2001 DA - 2001// TI - Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse JO - J Clin Oncol VL - 19 UR - https://doi.org/10.1200/JCO.2001.19.13.3244 DO - 10.1200/JCO.2001.19.13.3244 ID - Sievers2001 ER - TY - JOUR AU - Sievers, E. L. PY - 1999 DA - 1999// TI - Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate JO - Blood VL - 93 ID - Sievers1999 ER - TY - JOUR AU - Petersdorf, S. H. PY - 2013 DA - 2013// TI - A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2013-01-466706 DO - 10.1182/blood-2013-01-466706 ID - Petersdorf2013 ER - TY - JOUR AU - Delaunay, J. PY - 2011 DA - 2011// TI - Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of aml patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study JO - Blood VL - 118 ID - Delaunay2011 ER - TY - JOUR AU - Burnett, A. K. PY - 2011 DA - 2011// TI - Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.31.4310 DO - 10.1200/JCO.2010.31.4310 ID - Burnett2011 ER - TY - JOUR AU - Burnett, A. K. PY - 2012 DA - 2012// TI - Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2012.42.2964 DO - 10.1200/JCO.2012.42.2964 ID - Burnett2012 ER - TY - JOUR AU - Hills, R. K. PY - 2014 DA - 2014// TI - Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70281-5 DO - 10.1016/S1470-2045(14)70281-5 ID - Hills2014 ER - TY - STD TI - Mylotarg Medical Review(s). 2017; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761060Orig1s000Orig1Orig2s000MedR.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761060Orig1s000Orig1Orig2s000MedR.pdf ID - ref103 ER -